Maren Goeckenjan

Dr. Maren Goeckenjan

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2016 in Geburtshilfe und Frauenheilkunde
Verified
Journal Article
Open access
PDF file
DFD. Fischer
D. Fischer
CRC. Reisenbüchler
C. Reisenbüchler
SRS. Rösner
S. Rösner
JHJ. Haussmann
J. Haussmann
PWP. Wimberger
P. Wimberger
MGMaren Goeckenjan
Maren Goeckenjan
The polycystic ovary syndrome is a common endocrine disorder which influences outcome and potential risks involved with controlled ovarian stimulation for artificial reproductive techniques (ART). Concrete practical recommendations for the dosage of gonadotropins, the preferred protocol and preventive methods to avoid ovarian hyperstimulation syndrome (OHSS) are lacking. We present retrospective data of 235 individually calculated gonadotropin low-dose stimulations for ART in a single center from 2012 to 2014. Clinical data and outcome parameter of patients diagnosed with PCOS according to Rotterdam criteria (n = 39) were compared with patients without PCOS (n = 196). The starting dose of gonadotropins was individually calculated depending on patientsʼ age, BMI, ovarian reserve, ovarian response in previous cycles, and diagnostic criteria of PCOS. Mean age and duration of infertility did not differ between the groups, whereas mean BMI (p = 0.007) and AMH (p < 0.001) were higher in the PCOS-group. A lower mean FSH-starting and maximum dose was administered to women with PCOS (p < 0.001). The biochemical pregnancy rate of 42.4 % and the clinical pregnancy rate of 32.2 % for PCOS-patients did not differ from those of the control group (42.2 % and 34.4 % respectively). Neither mild, nor moderate or severe manifestation of OHSS occurred significantly more often in patients with PCOS. Our study supports the use of a calculated low-dose FSH-stimulation strategy in ART for patients with PCOS. Further randomized clinical trials should confirm this strategy and lead to define individual risk factors for OHSS, which can be used for recommendation of safer ART-techniques like in vitro maturation. Das polyzystische Ovarsyndrom (PCOS) ist eine häufige endokrinologische Störung der Frau, die erhebliche Auswirkungen auf Erfolg und potenzielle Risiken einer Gonadotropinstimulation bei künstlicher Befruchtung hat. Klare praktische Empfehlungen für die FSH-Dosierung und das optimale Stimulationsprotokoll zur Vermeidung eines OHSS fehlen weitgehend. Retrospektiv wurden Zyklen von 235 Patientinnen, die von 2012 bis 2014 für eine IVF/ICSI kontrolliert stimuliert wurden, analysiert. Klinische Daten der PCOS-Patientinnen (n = 39) wurden mit denen ohne PCOS (n = 196) verglichen. Die Gonadotropin-Startdosierung orientierte sich am Alter der Patientinnen, dem BMI, der ovariellen Reserve, Stimulationsverläufen in Vorzyklen und diagnostischen Kriterien des PCOS. Durchschnittliches Alter und Dauer der Infertilität unterschieden sich nicht signifikant zwischen den beiden Gruppen. Der durchschnittliche BMI (p = 0,007) und basale AMH-Wert (p < 0,001) lag bei Frauen mit PCOS höher. Bei ihnen fand sich eine signifikant niedrigere FSH-Start- und Maximaldosis (p < 0,001). Die Gesamtdosis verwendeter Gonadotropineinheiten sowie der maximale Östradiolspiegel jedoch unterschieden sich nicht. Auch die biochemischen und klinischen Schwangerschaftsraten von 42,2 und 32,2 % bei PCOS-Patientinnen wichen nicht signifikant von den Ergebnissen der Kontrollgruppe ab (42,2 und 34,4 %). Weder leichte noch moderate oder schwere Ausprägungen des OHSS kamen häufiger in einer der beiden Gruppen vor. Unsere Studie schlägt eine kalkulierte, niedrigdosierte Stimulationsstrategie mit Dosissteigerung in kleinen Schritten vor. Durch weitere randomisierte, kontrollierte klinische Studie sollte diese Strategie überprüft werden und individuelle Risikofaktoren erkannt werden, die in Einzelfällen als Indikation zu anderen sicheren Methoden der ART wie der In-vitro-Maturation genutzt werden können.

6 May 2020 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
MGMaren Goeckenjan
Maren Goeckenjan
AFA. Freis
A. Freis
KGK. Glaß
K. Glaß
JSJ. Schaar
J. Schaar
ITI. Trinkaus
I. Trinkaus
AGA. Germeyer
A. Germeyer
Purpose: Due to modern and individualised treatments, women at reproductive age have a high survival rate after cancer therapy. What are pregnancy and birth rates of women after cancer and how often do they use cryopreserved ovarian tissue or gametes? Methods: From 2007 to 2015, 162 women aged 26.7 ± 6.9 years were counselled for fertility preservation at a single University Fertility Centre. A questionnaire study was performed in average 3 and 6 years after the diagnosis of cancer. The women were asked about their fertility, partnership, family planning, and pregnancy history. 72 women (51%) answered a written questionnaire in 2016. 59 women were reached again by phone in 2019 (82%). Results: The preferred method of fertility preservation was ovarian tissue cryopreservation (n = 36, 50%); none of the women had ovarian hyperstimulation in order to cryopreserve oocytes. About 3 years after treatment, 37 women of 72 women (51%) of the women with a mean age of 29.9 years had a strong wish to conceive. 21/72 (29%) had actively tried to conceive after successful cancer treatment; eight women (11%) were already pregnant or had children. Six years after cancer diagnosis 16/59 (27%) women had ongoing anticancer treatment. 12/59 (20%) were pregnant or had children, while 39% (23/59) had no menstrual cycle. Only one woman used her cryopreserved ovarian tissue, but did not become pregnant. Conclusion: After cancer and gonadotoxic treatment, women’s desire to have a child is substantial. In this study, the rate of spontaneous pregnancies and births was 20% 6 years after gonadotoxic therapies. Not every woman, however, has the opportunity to conceive: factors impairing fertility include ongoing cancer treatment or persistent disease, no partner, no menstrual cycle, as well as other reasons for infertility.

3 October 2024 in Blood
Verified
Journal Article
Open access
KSKatja Sockel
Katja Sockel
ANAnnika Neu
Annika Neu
MGMaren Goeckenjan
Maren Goeckenjan
MDMarkus Ditschkowski
Markus Ditschkowski
IHInken Hilgendorf
Inken Hilgendorf
JSJohannes Schetelig
Johannes Schetelig
Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy and birth rates in a contemporary cohort, we conducted a national multicenter study using data from the German Transplant Registry, focusing on adult women aged 18 to 40 years who underwent alloHCT between 2003 and 2018. Of 2654 women who underwent transplantation, 50 women experienced 74 pregnancies, occurring at a median of 4.7 years after transplant. Fifty-seven of these resulted in live births (77%). The annual first birth rate among HCT recipients was 0.45%, which is >6 times lower than in the general population. The probability of a live birth 10 years after HCT was 3.4%. Factors associated with an increased likelihood of pregnancy were younger age at alloHCT, nonmalignant transplant indications, no total body irradiation or a cumulative dose of <8 Gy, and nonmyeloablative/reduced-intensity conditioning. Notably, 72% of pregnancies occurred spontaneously, with assisted reproductive technologies used in the remaining cases. Preterm delivery and low birth weight were more common than in the general population. This study represents the largest data set reporting pregnancies in a cohort of adult female alloHCT recipients. Our findings underscore a meaningful chance of pregnancy in alloHCT recipients. Assisted reproductive technologies techniques are important and funding should be made available. However, the potential for spontaneous pregnancies should not be underestimated, and patients should be informed of the possibility of unexpected pregnancy despite reduced fertility. Further research is warranted to understand the impact of conditioning decisions on fertility preservation.

19 August 2013 in Gynecological Endocrinology
Verified
Journal Article
Closed access
MGMaren Goeckenjan
Maren Goeckenjan
SRS. Rösner
S. Rösner
BTB. Toth
B. Toth
TST. Strowitzki
T. Strowitzki
AGA. Germeyer
A. Germeyer
Fertility preservation prior to gonadotoxic chemotherapy by cryopreservation of the ovarian tissue and controlled ovarian stimulation can be effective immediately after induced abortion in the first trimenon. In a reproductive endocrinology and infertility unit of a tertiary care university-based medical centre (University Hospital of Heidelberg) a 37-year-old women with breast cancer was counseled for fertility preservation. Cryopreservation of ovarian tissue, followed by ovarian stimulation for planned intracytoplasmatic sperm injection (ICSI), transvaginal oocyte aspiration and cryopreservation of fertilized eggs was performed in spite of persistently elevated human chorionic gonadotropin (hCG)-levels after induced abortion. Twenty-four fertilized oocytes with a fertilization rate of 92% were cryopreserved. Ovarian stimulation and oocyte cryopreservation can be successfully performed with good results immediately after miscarriage, despite persistent high hCG-levels.

14 July 2020 in Geburtshilfe und Frauenheilkunde
Verified
Journal Article
Open access
PDF file
MGMaren Goeckenjan
Maren Goeckenjan
ESEsther Schiwek
Esther Schiwek
PWPauline Wimberger
Pauline Wimberger
Introduction Ovulatory dysfunction is a major cause of female infertility. We evaluated the use of continuous body temperature monitoring with a vaginal biosensor to improve standard diagnostic procedures for determining ovulatory dysfunction. Material and Methods This prospective interventional study was performed in a reproductive medicine department of a university hospital. The menstrual cycles of 51 women with infertility were monitored and analysed using three different strategies: sonographic and hormonal assessment (standard approach), continuous core body temperature measurement and analysis using the algorithm of OvulaRing, and lowest daily body temperature measurement monitored with a vaginal biosensor and analysed based on the body temperature curves used in natural family planning. Results Statistically significant differences were found in the temperature curves of women with luteal phase deficiency and polycystic ovary syndrome compared to women with normal menstrual cycles. The analysis of individual cyclofertilograms can be used to detect cycle phases and estimate the date of ovulation. Conclusions Continuous body temperature monitoring with a vaginal biosensor can improve the standard diagnostic procedures used to determine ovulatory dysfunction, especially if dysfunction is due to luteal phase deficiency and polycystic ovary syndrome. Analysis of the lowest daily body temperature combined with the basal body temperature measurements used in fertility awareness methods may be equieffective to continuous body temperature measurements with OvulaRing. The results of this study show that a revised diagnostic approach using fewer hormonal assessments combined with continuous body temperature monitoring can reduce the number of appointments in an infertility clinic as well as the costs.

1 September 2021 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
MGMaren Goeckenjan
Maren Goeckenjan
DMDaria Madej
Daria Madej
AKAnna Klimova
Anna Klimova
PWPauline Wimberger
Pauline Wimberger
CBCahit Birdir
Cahit Birdir
KGKatrin Glaß
Katrin Glaß